Accutar Biotechnology, Inc.
- Biotech or pharma, therapeutic R&D
Accutar is NJ biotech company. Our pipeline includes AC0699, ph1 oral chimeric degrader for breast cancer (with fast track designation), selective CDK4 inhibitor in IND enabling, and a portfolio of clinical / precllinical stage degraders and inhibitors